Arbutus Biopharma Corporation (ABUS) Financials
ABUS Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2024-03-31 | 150.3 million | 35.7 million |
| 2023-12-31 | 144.4 million | 38.4 million |
| 2023-09-30 | 158.6 million | 39.3 million |
| 2023-06-30 | 176.8 million | 42.1 million |
ABUS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2024-03-31 | -19.4 million | ? |
| 2023-12-31 | -16.2 million | 1.7 million |
| 2023-09-30 | -21.8 million | 2.5 million |
| 2023-06-30 | -20.4 million | 3.0 million |
ABUS Net Income
No data available :(
ABUS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2024-03-31 | 129.2 million | - | - |
| 2023-12-31 | 126.0 million | - | 1.8 million |
| 2023-09-30 | 134.2 million | - | 1.9 million |
| 2023-06-30 | 152.5 million | - | 2.0 million |
ABUS Shares Outstanding
ABUS Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2024-03-31 | 95000 | 15.4 million | 5.3 million | -355000 |
| 2023-12-31 | 13360 | 17.6 million | 5.1 million | -359000 |
| 2023-09-30 | 32000 | 20.2 million | 5.8 million | - |
| 2023-06-30 | 859000 | 17.7 million | 6.0 million | - |
ABUS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2024-03-31 | 1.5 million | 355000 |
| 2023-12-31 | 2.1 million | 359000 |
| 2023-09-30 | 4.7 million | 369000 |
| 2023-06-30 | 4.7 million | 342000 |
ABUS
Price: $2.80
52 week price:
Earnings Per Share: -0.44 USD
P/E Ratio: -5.13
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 545700
Ebitda: -10.9 millionMarket Capitalization: 488.3 million